Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
Associated filings
- 24 Jan 23 EFFECT Notice of effectiveness
- 23 Jan 23 424B3 Prospectus supplement
- 6 Jan 23 S-4/A Registration of securities issued in business combination transactions (amended)
-
19 Dec 22 S-4/A Registration of securities issued in business combination transactions (amended)
- 10 Nov 22 S-4 Registration of securities issued in business combination transactions
ELVN similar filings
Filing view
External links
Exhibit 23.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the use in this Registration Statement No. 333-268300 on Form S-4 of our report dated November 8, 2022, relating to the financial statements of Enliven Therapeutics, Inc. We also consent to the reference to us under the heading “Experts” in such Registration Statement.
/s/ Deloitte & Touche LLP
San Jose, California
December 16, 2022